Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Cyst Fibros. 2021 Aug 26;21(1):115–122. doi: 10.1016/j.jcf.2021.08.005

Table 1.

Practice definitions

Practice Definition Inclusion Criteria Ages at visit included Patients Eligible (No.) Visits Eligible (No.)
Dietitian Assessment
Patients documented as seen by a dietitian at or subsequent visit to inadequate weight gain At least 1 inadequate weight gain visit 0–24 months 216 808
Calorie Intake Assessment
Calorie intake at visit subsequent to inadequate weight gain should be greater than minimum age-expected calories in formula-fed infants. • Exclusively formula fed
• Available calorie count at visit subsequent to inadequate weight gain
0–12 months 110 145
Calorie Density Increase
Formula calorie density should be reported as maintains or greater than at least 24 kcal/30 mL in subsequent visit to inadequate weight gain. Formula calorie density in kcal/30 mL reported in CFFPR in visit subsequent to inadequate weight gain 0–24 months 101 161
PERT Dose Increase
PERT dose increases to greater than 300 units lipase/kg body weight compared to prior enzyme dose in subsequent visit to inadequate weight gain. • Pancreatic insufficient (PI) as defined by fecal elastase (FE) <200 ug/g or 2 CFTR variants associated with pancreatic insufficiency
• PERT dose recorded at visit subsequent to inadequate weight gain
0–12 months 152 270
Follow up clinic visit timing
Subsequent visit to inadequate weight gain seen sooner than routine follow up for agea: At least 1 inadequate weight gain visit 0–24 months 216b 808
 0–6 months old
 <3.5 weeks (26 days)
142 216
 6–12 months old
 < 6 weeks (43 days)
100 133
 12–24 months old
 < 12 weeks (85 days)
203 459
a

Current recommendations for routine follow-up: monthly for infants < 6 months of age; every 2 months for infants 6–12 months of age; every 3 months for children 12–24 months of age

b

Patients eligible at more than one age group for follow up